Chao Zhan

Chao Zhan

Auto-generated profile, based on publicly available information

Chao Zhan

Department of Rehabilitation Medicine, Huangshi Hospital of Traditional Chinese Medicine, Hubei, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
SLShu-Ting Liu
Shu-Ting Liu
CZChao Zhan
Chao Zhan
YMYun-Jing Ma
Yun-Jing Ma
CGChao-Yang Guo
Chao-Yang Guo
WCWei Chen
Wei Chen
LFLei Fang
Lei Fang
There are several effective complementary and integrative therapies for patients with severe COVID-19. The trial aims to evaluate the efficacy and advantages of the qigong exercise and acupressure rehabilitation program (QARP) for treating patients with severe COVID-19. A total of 128 patients with COVID-19 aged 20 to 80 years were recruited and randomly allocated in a 1:1 ratio to receive QARP plus standard therapies or standard therapies alone. QARP consisted of acupressure therapy and qigong exercise (Liu Zi Jue). The primary outcome was measured with the modified Medical Research Council (mMRC) dyspnea scale, and the secondary outcomes included the modified Borg dyspnea scale (MBS), fatigue Scale-14 (FS-14), patient health questionnaire-9 scale (PHQ-9), duration of respiratory symptoms, and vital signs. In total, 128 patients completed the clinical trial. The QARP group and standard therapies group showed significant improvements in vital signs (except blood pressure) and clinical scales compared with baseline (p<0.05). The QARP group also showed more significant improvement in the mMRC dyspnea scale (-1.8 [-2.1, -1.6], p=0.018) and modified Borg dyspnea scale (-3.7 [95% confidence intervals (CI) -4.3, -3.1], p=0.045). The duration of cough was 14.3 days (95% CI 12.6, 16.1, p=0.046), and the length of hospital stay was 18.5 days (95% CI 17.0, 20.0, p=0.042) in the QARP group, both of which were significantly reduced compared with the standard therapies group (p<0.05). QARP plus standard therapies improved lung function and symptoms such as dyspnea and cough in patients with severe COVID-19 and shortened the length of hospital stay. Therefore, QARP may be considered an effective treatment option for patients with severe COVID-19. Clinical Research Information Service Identifier: ChiCTR2000029994

6 September 2024 in Integrative Medicine Research
Verified
Journal Article
Open access
SLShuting Liu
Shuting Liu
RZRanran Zhu
Ranran Zhu
CYChongjie Yao
Chongjie Yao
CZChao Zhan
Chao Zhan
JWJinxiang Wang
Jinxiang Wang
LFLei Fang
Lei Fang
Most clinical trials have reported significant short-term effects of traditional medicine therapies on COVID-19 patients. However, there is no clinical trial to determine the long-term effects of traditional medicine therapies on severe COVID-19 patients. A total of 128 patients with severe COVID-19, who were recruited in our previous clinical trial following hospital discharge, were monitored at months 14 and 28. This trial aims to evaluate the long-term effect of an early Qigong exercise and acupressure rehabilitation program on patients with severe COVID-19.The intervention group received qigong exercise and acupressure therapy, plus standard therapies. The control group received standard therapies.The study was a single-center, parallel, randomized, prospective follow-up study. The outcomes of the study included changes in the modified Borg dyspnea scale (MBS), the modified Medical Research Council dyspnea scale (mMRC), the patient health questionnaire-9 scale (PHQ-9), the activity of daily living (ADL), the remaining clinical symptoms and any intervention related adverse events. The intervention group showed a statistically significant improvement in the mMRC scores (−0.4, 95 % CI (−0.6, 0.2), P < 0.001) and the MBS scores (−0.6, 95 % CI (−0.9, −0.3), P < 0.001) after 14 months of discharge compared with the control group. At 28 months of discharge, the intervention group, compared with the control group alone, significantly increased their MBS scores (−0.4, 95 % CI (−0.7, −0.1), P = 0.024) and a significantly decreased positive rate of dyspnea symptoms after 14 months of discharge (P < 0.05). However, ADL and PHQ-9 scores showed no significant difference between the two groups during the follow-up (P > 0.05). QARP had long-term sustained efficacy for dyspnea, chest tightness, and cough in patients with COVID-19, especially in young and middle-aged patients, and the effect was significant at the 14th month of follow-up. This trial was registered at the China Clinical Trial Registry (ChiCTR2100044572).